Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 21,430 matching trials from the live ClinicalTrials.gov search.
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, docetaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Alopecia Areata
Interventions
Crisaborole Topical Ointment, Placebo Topical Ointment
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alport Syndrome
Interventions
Placebo Oral Capsule, Bardoxolone Methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 60 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
Conditions
Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
Interventions
Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Laguna Hills, California • Iowa City, Iowa + 6 more
Conditions
Colorectal Cancer
Interventions
capecitabine, Oxaliplatin, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Conditions
HIV Infections
Interventions
Oral HIV screening, Fingerstick HIV screening
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mesa, Arizona • Anaheim, California • Lancaster, California + 12 more
Conditions
Heart Failure
Interventions
vicadrostat, empagliflozin, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
94
States / cities
Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

NCT03536143
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Topical beremagene geperpavec, Placebo gel
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Prostate Cancer Metastatic, Prostate Cancer, CRPC
Interventions
Enhertu
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Conditions
Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
Interventions
talabostat mesylate tablets, gemcitabine
Drug
Lead sponsor
Point Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Florence, Alabama • Muscle Shoals, Alabama • Hartford, Connecticut + 20 more
Conditions
Pancreatic Adenocarcinoma
Interventions
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
Conditions
Transplant Rejection
Interventions
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine, quality-of-life assessment, DNA analysis, RNA analysis, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis, immunohistochemistry staining method, polymorphism analysis
Drug · Procedure · Genetic + 2 more
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
conventional surgery, tandutinib, pharmacological study, Tissue samples
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Conditions
Metastatic Uveal Melanoma
Interventions
ZIV-Aflibercept, Cemiplimab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Conditions
Neuroblastoma
Interventions
Tipifarnib, Naxitamab
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
1 Year to 21 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
12
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 9 more
Conditions
Lung Cancer
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
La Verne, California • Rochester, New York • Canton, Ohio + 4 more
Conditions
Sarcoma
Interventions
filgrastim, doxorubicin hydrochloride, ifosfamide, mesna, vincristine sulfate, conventional surgery, brachytherapy, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
7
States / cities
Wichita, Kansas • New Orleans, Louisiana • Memphis, Tennessee + 4 more
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

NCT03003247
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
364 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
20
States / cities
Encino, California • Lake Mary, Florida • Miami, Florida + 15 more